Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn's Disease.
- Author:
Kyoichi KATO
1
;
Ken FUKUNAGA
;
Koji KAMIKOZURU
;
Shinichiro KASHIWAMURA
;
Nobuyuki HIDA
;
Yoshio OHDA
;
Naohisa TAKEDA
;
Koji YOSHIDA
;
Masaki IIMURO
;
Yoko YOKOYAMA
;
Risa KIKUYAMA
;
Hiroto MIWA
;
Takayuki MATSUMOTO
Author Information
1. Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan. kebe@hyo-med.ac.jp
- Publication Type:Original Article
- Keywords:
Crohn's disease;
Infliximab;
Transforming growth factor-beta1;
RANTES;
Regulatory T-cell
- MeSH:
Antibodies;
Antibodies, Monoclonal;
Chemokine CCL2;
Chemokine CCL5;
Chemokines;
Crohn Disease;
Cytokines;
Humans;
Immune System;
Interferons;
Interleukin-10;
Interleukin-13;
Interleukin-6;
Interleukin-8;
Interleukins;
Lymphocytes;
Macrophages;
Mesalamine;
Remission Induction;
T-Lymphocytes, Regulatory;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Gut and Liver
2011;5(1):37-45
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Infliximab (IFX), an antibody to tumor necrosis factor, (TNF)-alpha has efficacy in treating Crohn's disease (CD). However, knowledge of the potential effects of IFX on patients' immune profiles is lacking. The purpose of this study was to reveal the immunological effects of IFX. METHODS: Twenty-two patients with a CD activity index (CDAI) of 194.2+/-92.9 and an average duration of disease of 3.26 months and 21 healthy controls were included. Patients were to have their first IFX remission induction therapy with 3 infusions (5 mg/kg) at weeks 0, 2, and 6. Oral 5-aminosalicylic acid was the only ongoing medication in the patient population. Blood samples at baseline, 12 hours after the first infusion and at week 14 were labeled with anti-CD4/CD25 antibodies for immunohistochemical measurement of regulatory T-cells (Treg). Serum cytokines and chemokines were measured by suspension array and ELISA. RESULTS: CDAI significantly decreased prior to the second IFX infusion (p<0.001). Clinical remission rates were 77.3% and 91% by the second and third infusions, respectively. At baseline, interleukin (IL)-6 (p<0.03), IL-8 (p<0.03), IL-10 (p=0.050), IL-13 (p<0.01), transforming growth factor-beta1 (p<0.01), and 'regulated on activation, normal T cell expressed and secreted' (RANTES) (p<0.01) were elevated in patients. After the initial IFX infusion, TNF-alpha (p<0.04), IL-6 (p<0.03), interferon (IFN)-gamma (p<0.04), IFN-gamma-inducible protein-10 (p<0.01), monocyte chemoattractant protein-1 (p<0.01), macrophage inflammatory protein-1beta (p<0.01), and RANTES (p<0.01) were decreased. IFX infusion was associated with an increase in Treg (p<0.01) and a decrease in the Th1 (IFN-gamma)/Th2 (IL-4) ratio (p<0.03). CONCLUSIONS: IFX use was associated with restoration of the Th1/Th2 balance after a single infusion and seemed to promote induction of naive Th0 lymphocytes to Treg. This knowledge should have clinical relevance.
